Skip to main content
Equibles
PDSB logo

PDSB · PDS Biotechnology Corp

Track PDSB — free

Use PDSB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PDSB

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.23 0.00 (-1.11%) At close · Aug 14
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result of these uncertainties, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements.”
View the 10-Q filed Aug 13, 2026
Market Cap
$13.51M
Shares
55.97M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.23 Open$0.23 Day$0.23–0.24 52W close$0.23–1.43 Avg vol 30d1.6M Short int1.8M · 3.3% float · 10.5d Short vol24% Last earningsMay 13, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 13

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −73%
      below
      Price vs 50-day avg −71%
      below
      RSI (14) 17
      oversold
      MACD trend Negative
      52-week position 0%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −69%
      trailing
      6-month return −64%
      trailing
      YTD return −70%
      this year
      Relative strength −78%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      +21% holders QoQ · +14 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      3.28% of float · ▲ +12.4% MoM · 10.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      52 holders — mid 3-yr range
      Squeeze score 65
      elevated · 0–100
      Fundamentals
      Strong
      EPS growth +28%
      Y/Y
      Free cash flow $-27.8M
      Balance sheet $21.2M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 117%
      annualized · 1-yr
      Max drawdown −84%
      past year
      ATR 33.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −73% Bearish
      Price vs 50-day avg
      −71% Bearish
      RSI (14)
      17 Neutral
      MACD trend
      Negative Bearish
      52-week position
      0% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      +21% holders QoQ · +14 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      3.28% of float · ▲ +12.4% MoM · 10.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      52 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $0 Now $0 · 0% Range high $1
      vs 200-day avg -73% vs 50-day avg -71%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PDSB
      PDS Biotechnology Corp
      this stock
      		$13.51M -70.1% — — 3.3%
      ONC
      BeOne Medicines Ltd.
      		 $530.72B +14.4% +22179.2% 816.0 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $133.25B +11.6% +46.2% 30.6 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.16B +4.1% +20.8% 19.8 3.3%
      ARGX
      Argenx SE
      		 $52.69B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      52
      % held
      14.3%
      Net QoQ
      +2.6M sh
      Top holder
      VANGUARD CAPITAL MANAGEME…
      Held Float
      View
      Held by Funds
      Fund positions
      17
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      1.8M
      Days to cover
      10.5d
      Change
      +202.4K sh
      View
      Short Volume
      Short vol %
      24%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      7.9K
      Value
      $6.9K
      As of
      Jul 2, 2026
      View
      Off-Exchange
      Off-exchange %
      56.5%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Net income (FY)
      $-34.5M
      EPS diluted
      $-0.74
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 14, 2026
      This year
      23
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PDSB -70.3% -68.6% -64.0% -66.4% -70.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -70.7% -73.1% -77.7% -70.3% -83.9%
      Key facts CIK 1472091 CUSIP 70465T107 13F (30d) 49 filings 49 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)